Fig. 2

Allergic manifestations evaluated in whey- or PE-sensitized mice after receiving SCIT and OIT. a, b Acute allergic skin response measured as Δ ear swelling 1 h after i.d. challenge. c Anaphylactic shock symptom scores determined 30 min after i.d. challenge in CMA model. d Body temperature measured 30 min after i.d. challenge in CMA model. e, f Concentrations of mMCP-1 in serum collected 30 min after i.g. challenge. g, h Change in body temperature after i.p. challenge in PNA model. i Anaphylactic shock symptom scores determined 40 min after i.p. challenge in PNA model. Data are represented as mean ± SEM n = 6–8 mice/group. Statistical analysis was performed using one-way ANOVA and Dunnett’s post hoc test for multiple comparisons or a repeated measures two-way ANOVA and Dunnett’s post hoc test for multiple comparisons with matched values for the temperature curve in g–h. ^#P < 0.05; ^##P < 0.01; ^###P < 0.001; ^####P < 0.0001 compared to sham control. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 compared to whey- or PE-sensitized control. OIT oral immunotherapy, SCIT subcutaneous immunotherapy, PE peanut extract; CT cholera toxin, mMCP-1 mucosal mast cell protease-1, IT immunotherapy